IRIS Accounts Production v26.1.10.61 12997974 Board of Directors 1.4.25 31.3.26 31.3.26 0 0 false true false false true false A Ordinary 1.00000 B Ordinary 1.00000 C Ordinary 1.00000 D Ordinary 1.00000 60471 43283 206775 182728 174585 165540 92661 60471 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 12997974 2025-03-31 12997974 2026-03-31 12997974 2025-04-01 2026-03-31 12997974 2024-03-31 12997974 2024-04-01 2025-03-31 12997974 2025-03-31 12997974 ns15:EnglandWales 2025-04-01 2026-03-31 12997974 ns14:PoundSterling 2025-04-01 2026-03-31 12997974 ns10:Director1 2025-04-01 2026-03-31 12997974 ns10:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 12997974 ns10:SmallEntities 2025-04-01 2026-03-31 12997974 ns10:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 12997974 ns10:SmallCompaniesRegimeForDirectorsReport 2025-04-01 2026-03-31 12997974 ns10:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 12997974 ns10:FullAccounts 2025-04-01 2026-03-31 12997974 ns10:OrdinaryShareClass2 2025-04-01 2026-03-31 12997974 ns10:OrdinaryShareClass3 2025-04-01 2026-03-31 12997974 ns10:OrdinaryShareClass4 2025-04-01 2026-03-31 12997974 ns10:OrdinaryShareClass5 2025-04-01 2026-03-31 12997974 ns10:Director1 41 2025-03-31 12997974 ns10:Director1 41 2024-03-31 12997974 ns10:Director1 41 2025-04-01 2026-03-31 12997974 ns10:Director1 41 2024-04-01 2025-03-31 12997974 ns10:Director1 41 2026-03-31 12997974 ns10:Director1 41 2025-03-31 12997974 ns10:Director2 2025-04-01 2026-03-31 12997974 ns10:Director3 2025-04-01 2026-03-31 12997974 ns10:Director4 2025-04-01 2026-03-31 12997974 ns10:RegisteredOffice 2025-04-01 2026-03-31 12997974 ns5:CurrentFinancialInstruments 2026-03-31 12997974 ns5:CurrentFinancialInstruments 2025-03-31 12997974 ns5:ShareCapital 2026-03-31 12997974 ns5:ShareCapital 2025-03-31 12997974 ns5:RetainedEarningsAccumulatedLosses 2026-03-31 12997974 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 12997974 ns5:CostValuation 2025-03-31 12997974 ns5:AdditionsToInvestments 2026-03-31 12997974 ns5:RevaluationsIncreaseDecreaseInInvestments 2026-03-31 12997974 ns5:CostValuation 2026-03-31 12997974 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2026-03-31 12997974 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 12997974 ns10:OrdinaryShareClass2 2026-03-31 12997974 ns10:OrdinaryShareClass3 2026-03-31 12997974 ns10:OrdinaryShareClass4 2026-03-31 12997974 ns10:OrdinaryShareClass5 2026-03-31 12997974 2 ns10:Director2 2025-03-31 12997974 2 ns10:Director2 2024-03-31 12997974 2 ns10:Director2 2025-04-01 2026-03-31 12997974 2 ns10:Director2 2024-04-01 2025-03-31 12997974 2 ns10:Director2 2026-03-31 12997974 2 ns10:Director2 2025-03-31

REGISTERED NUMBER: 12997974 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

FOR

YORKSHIRE PHARMA HOLDINGS LTD

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

YORKSHIRE PHARMA HOLDINGS LTD

COMPANY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2026

| DIRECTORS: | A K Atkinson

| C H E Atkinson

| A K Blake

| H I Atkinson

| REGISTERED OFFICE: | 12 Victoria Road

| Barnsley

| South Yorkshire

| S70 2BB

| REGISTERED NUMBER: | 12997974 (England and Wales)

| ACCOUNTANTS: | Xeinadin Barnsley Limited

| 12 Victoria Road

| Barnsley

| South Yorkshire

| S70 2BB

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

BALANCE SHEET

31 MARCH 2026

| 31.3.26 | 31.3.25 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Investments | 4 | 4,617,360 |  | 3,675,395 |  |

CURRENT ASSETS

Debtors | 5 | 92,661 |  | 288,146 |  |

Cash at bank | 124,019 |  | 100 |  |

216,680 |  | 288,246 |  |

CREDITORS

Amounts falling due within one year | 6 | 274,910 |  | 23,500 |  |

NET CURRENT (LIABILITIES)/ASSETS | (58,230 | ) | 264,746 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 4,559,130 |  | 3,940,141 |  |

CAPITAL AND RESERVES

Called up share capital | 7 | 2,600,099 |  | 2,600,099 |  |

Retained earnings | 1,959,031 |  | 1,340,042 |  |

SHAREHOLDERS' FUNDS | 4,559,130 |  | 3,940,141 |  |

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

BALANCE SHEET - continued

31 MARCH 2026

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 August 2026 and were signed on its behalf by:

A K Atkinson - Director

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

1. | STATUTORY INFORMATION

| Yorkshire Pharma Holdings Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest pound.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

| Preparation of consolidated financial statements

| The Financial Statements contain information about Fleet Support Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group . The company has taken the option under Section 398 of the Companies Act 2006 not to prepare financial statements.

| Significant judgements and estimates

| No judgements have been made in the process of applying the below accounting policies that have had the most significant effect on amounts recognised in the financial statements.

| There are no key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year.

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at historic cost. The fair value of investments in subsidiary undertakings, in the opinion of the directors, cannot be measured reliably without undue cost or effort.

| As such, investments in subsidiary undertakings are accounted for using the cost model.

| Regular impairment reviews are undertaken by the directors.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

2. | ACCOUNTING POLICIES - continued

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2025 - NIL).

4. | FIXED ASSET INVESTMENTS

| Shares in |

| group |  | Other |

| undertakings |  | investments |  | Totals

£ | £ | £ |

| COST OR VALUATION

| At 1 April 2025 | 3,675,395 |  | - |  | 3,675,395 |  |

| Additions | - |  | 1,000,000 |  | 1,000,000 |  |

| Revaluations | - |  | (58,035 | ) | (58,035 | ) |

| At 31 March 2026 | 3,675,395 |  | 941,965 |  | 4,617,360 |  |

| NET BOOK VALUE

| At 31 March 2026 | 3,675,395 |  | 941,965 |  | 4,617,360 |  |

| At 31 March 2025 | 3,675,395 |  | - |  | 3,675,395 |  |

| Cost or valuation at 31 March 2026 is represented by:

| Shares in |

| group |  | Other |

| undertakings |  | investments |  | Totals

£ | £ | £ |

| Valuation in 2026 | 3,675,395 |  | 941,965 |  | 4,617,360 |  |

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

4. | FIXED ASSET INVESTMENTS - continued

| If other investments had not been revalued they would have been included at the following historical cost:

| 31.3.26 |  | 31.3.25

£ | £ |

| Cost | 1,000,000 |  | - |  |

| Other investments were valued on an open market basis on 31 March 2026 by St James Place .

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.3.26 |  | 31.3.25

£ | £ |

| Amounts owed by group undertakings | - |  | 227,675 |  |

| Directors' current accounts | 92,661 |  | 60,471 |  |

92,661 |  | 288,146 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.3.26 |  | 31.3.25

£ | £ |

| Amounts owed to group undertakings | 274,910 |  | - |  |

| Other creditors | - |  | 23,500 |  |

274,910 |  | 23,500 |  |

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 31.3.26 |  | 31.3.25

| value: | £ | £ |

| 1,170,045 | A Ordinary | £1 | 1,170,045 |  | 1,170,045 |  |

| 1,170,044 | B Ordinary | £1 | 1,170,044 |  | 1,170,044 |  |

| 130,005 | C Ordinary | £1 | 130,005 |  | 130,005 |  |

| 130,005 | D Ordinary | £1 | 130,005 |  | 130,005 |  |

2,600,099 |  | 2,600,099 |  |

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

8. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

| The following advances and credits to directors subsisted during the years ended 31 March 2026 and 31 March 2025:

| 31.3.26 |  | 31.3.25

£ | £ |

| C H E Atkinson and A K Atkinson

| Balance outstanding at start of year | 60,471 |  | 43,283 |  |

| Amounts advanced | 206,775 |  | 182,728 |  |

| Amounts repaid | (174,585 | ) | (165,540 | ) |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | 92,661 |  | 60,471 |  |